Lv1
50 积分 2024-10-09 加入
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
3天前
已完结
Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study
3天前
求助中
PB0476 Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genetic Variants
4个月前
已完结
皖公网安备34019202002308
